Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE11A | Q9HCR9 | 7/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472447 | 0.92 | MAPT (0.43) | PDE11AKDRMAPTTP53LMNA | |
| SCHEMBL14770752 | 0.87 | MAPT (0.40) | PDE11AKDRMAPTTP53LMNA | |
| SCHEMBL13472457 | 0.79 | MAPT (0.43) | PDE11AMAPTTP53LMNAGABRA1 | |
| SCHEMBL13472306 | 0.76 | KDM4E (0.45) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL14770749 | 0.76 | EGFR (0.38) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL20573702 | 0.75 | LMNA (0.39) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL12590747 | 0.72 | KDR (0.40) | PDE11AKDRMAPTEGFR | |
| SCHEMBL13199821 | 0.71 | HSD17B10 (0.41) | PDE11AKDRMAPTTP53LMNA | |
| SCHEMBL13472307 | 0.69 | KDM5B (0.48) | MAPTTP53LMNAKMT2A | |
| SCHEMBL13472328 | 0.68 | MAP4K4 (0.55) | MAPTTP53LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | XOMA (US) LLC | 2015-03-19 | — | — | US | disclosed |
| US-8802657-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | PDE11A 3592/4885KDR 1384/4885MAPT 3659/4885 |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PDE11A 3592/4885KDR 1384/4885MAPT 3659/4885 |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PDE11A 3592/4885KDR 1384/4885MAPT 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.